“The change was primarily due to interest expense on our $150.0 million aggregate principal amount of convertible senior notes due 2030, which were issued during the third quarter of 2025, and partially offset by interest income on cash and short-term investme…”10-Q · May 14, 2026 ↗
CorMedix Inc.
CRMD
Market read
CorMedix Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 4 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
- CRMD's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if CRMD's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 4 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
- CRMD's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
- Latest annual revenue changed +617.0% year over year.
- Operating margin changed +99.6 percentage points in the latest annual period.
- Net margin changed +93.6 percentage points in the latest annual period.
- Operating cash flow covered net income at 1.07x in the latest annual period.
- Diluted shares increased 36.4% in the latest annual period.
- P/E is 89% below the available filing-peer median; determine whether growth and quality justify the difference.
- EV/sales is 78% below the available filing-peer median; determine whether growth and quality justify the difference.
Price as of Sep 10, 2026
7.95Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
Persistent and emerging business drivers
“Foreign exchange transaction income (loss) for the three and nine months ended September 30, 2025 and 2024 were due to the re-measuring of transactions denominated in a currency other than our functional currency.”10-Q · Nov 12, 2025 ↗
“In addition, general and administrative expense increased due to higher branded prescription drug fees driven by growth in product sales, as well as higher litigation-related costs.”10-Q · May 14, 2026 ↗
“Contract Revenue As a result of the Merger, we recognize revenue associated with Melinta’s license and collaboration agreements for the research and development and/or commercialization of its therapeutic products in the form of licensing fees, milestone paym…”10-Q · Nov 12, 2025 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 2.0× · EV/sales 1.6×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for CRMD. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for CRMD. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind CRMD
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
TGTTarget CorporationpartnerAug 7, 2025 ▾
“Under the terms and subject to the conditions set forth in the Merger Agreement, at the effective time of the Merger (the “Effective Time” and the date of the Effective Time, the “Closing Date”), the Company will (i) pay to the Melinta equityholders (includin…”
LGNDLigand Pharmaceuticals IncorporatedsupplierNov 12, 2025 ▾
“Additionally, Melinta has agreed to purchase our requirements of Captisol from Ligand for use in a Baxdela product, with pricing established pursuant to a tiered pricing schedule.”
TLPHFiling-linked nameinvesteeNov 12, 2025 ▾
“Other income represents the change in fair value for its marketable equity securities in Talphera, a publicly-traded biotechnology company, from the date that the stock was acquired to September 30, 2025.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
CRMD is currently a Follower in the organic co-movement group Financial Technology Solutions. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for CRMD; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.